|
|||||
|
|
Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis |
|
| Authors: | Kevin Robbins Robert Bissonnette Tomoko Maeda-Chubachi Li Ye Johnny Peppers Kelly Gallagher John E. Kraus |
| Affiliation: | 1. GSK, Collegeville, Pennsylvania;2. Innovaderm Research Inc, Montreal, Canada;3. Novan Inc, Morrisville, Raleigh;4. PRA Health Sciences, Raleigh;5. ICON plc, Research Triangle Park, North Carolina |
| Abstract: | |
| Keywords: | GSK2894512 psoriasis TAMA tapinarof therapeutic AhR (aryl hydrocarbon receptor) modulating agent AE adverse event AhR aryl hydrocarbon receptor BSA body surface area CI confidence interval PASI Psoriasis and Area Severity Index PASI75 ≥75 improvement in Psoriasis and Area Severity Index PGA Physician Global Assessment PASI Psoriasis Area and Severity Index IL interleukin TEAE treatment-emergent adverse event |
| 本文献已被 ScienceDirect 等数据库收录！ | |